2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
2
Phase 2/3
1
Status
Completed
2
Terminated
1
Sponsor Class
INDUSTRY
3
Study Type
Interventional
3
Sponsor
Cancer Type
Endocrine
2
Thoracic
1
NET
1
Head & Neck
1
Conditions
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Neuroendocrine Tumors
1
Neuroectodermal Tumors, Primitive
1
Neoplasms
1
Lung Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoid Tumor
1
Interventions
Cyclophosphamide
909
Carboplatin
786
Paclitaxel
741
pembrolizumab
741
Bevacizumab
715
Cisplatin
707
Gemcitabine
621
Docetaxel
583
Rituximab
558
Radiotherapy
546
Dexamethasone
510
Nivolumab
488
Doxorubicin
445
Fluorouracil
392
Capecitabine
382
Etoposide
357
Pemetrexed
336
Oxaliplatin
335
Cytarabine
334
Lenalidomide
327
Prednisone
327
Erlotinib Hydrochloride
323
fludarabine phosphate
315
Trastuzumab
305
Leucovorin
299
fludarabine
296
Vincristine
288
Bortezomib
284
Filgrastim
284
Cetuximab
275
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
3 trials
Recent
Start date
Enrollment
Has results
×
fosbretabulin
×
Clear all
NCT02132468
2017-12-05
GI-NETorPNET
Mateon Therapeutics
Phase 2
Completed
18 enrolled
10 charts
NCT00653939
2015-02-09
FALCON
Mateon Therapeutics
Phase 2
Completed
63 enrolled
18 charts
NCT00507429
2014-06-09
FACT
Mateon Therapeutics
Phase 2/3
Terminated
80 enrolled
10 charts